# OnCo record nct03093116 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03093116/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03093116", "NCT03093116" ;
  schema:name "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements"@en ;
  schema:alternateName "TRIDENT-1"@en ;
  schema:description "A phase 1/2 trial of Repotrectinib in advanced solid tumours, run by Turning Point Therapeutics, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03093116/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03093116>, <https://doi.org/10.1056/NEJMoa2302299> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2017-03-07" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/ros1-positive-nsclc/>, <https://onco.cc/cancers/ntrk-fusion-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/repotrectinib/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/profile-1001-ros1/>, <https://onco.cc/trials/nct02568267/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-trident-1-repotrectinib-nejm-2024/> .